Skip to main content

Table 4 WHO classification: OS of patients with MDS or AML receiving azacitidine front-line

From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

WHO diagnosis n Median OS, mo 95 % CI, mo p value
AML30+
AML20–30
MDS-RAEB-II
MDS-RAEB-I
111
79
96
53
10.9
13.1
18.9
23.7
7.5–14.3
9.8–16.5
12.7–25.1
14.4–33.0
<0.001a
AML30+
AML20–30
111
79
10.9
13.1
7.5–14.3
9.8–16.5
0.238
AML20–30
MDS-RAEB-II
79
96
13.1
18.9
9.8–16.5
12.7–25.1
0.010b
MDS-RAEB-II
MDS-RAEB-I
96
53
18.9
23.7
12.7–25.1
14.4–33.0
0.302
  1. aHR = 1.292; 95 % CI 1.168, 1.430
  2. bHR = 1.645; 95 % CI 1.123, 2.409